Abstract
The serum samples and corresponding cervical swabs were collected from 50 women with genital warts from Tianjin city, China. The neutralizing antibodies against HPV-16, -18, -58, -45, -6 and -11 in serum samples were tested by using pseudovirus-based neutralization assays and HPV DNAs in cervical swabs were also tested by using a typing kit that can detect 21 types of HPV. The results revealed that 36% (18/50) of sera were positive for type-specific neutralizing antibodies with a titer range of 160–2560, of which 22%(11/50), 12%(6/50), 10%(5/50), 4%(2/50), 4%(2/50) and 2%(1/50) were against HPVs -6, -16, -18, -58, -45 and -11, respectively. Additionally, 60% (30/50) of samples were HPV DNA-positive, in which the most common types detected were HPV-68(18%), HPV-16(14%), HPV-58(12%), HPV-33(8%) and HPV-6, HPV-11, HPV-18 and HPV-52 (6% each). The concordance between HPV DNA and corresponding neutralizing antibodies was 56% (28/50) with a significant difference (P<0.05). The full-length sequences of five HPV types (HPV -42, -52, -53, -58 and -68) were determined and exhibited 98%–100% identities with their reported genomes. The present data may have utility for investigating the natural history of HPV infection and promote the development of HPV vaccines.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baay M F, Tjalma W A, Weyler J, et al. 2001. Human papillomavirus infection in the female population of Antwerp, Belgium: prevalence in healthy women, women with premalignant lesions and cervical cancer. Eur J Gynaecol Oncol, 22: 204–208.
Bergeron C, Barrasso R, Beaudenon S, et al. 1992. Human papillomaviruses associated with cervical intrae-pithelial neoplasia. Great diversity and distinct distribution in low- and high-grade lesions. Am J Surg Pathol, 16: 641–649.
Bosch F X, Manos M M, Munoz N, et al. 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst, 87: 796–802.
Brown D R, Schroeder J M, Bryan J T, et al. 1999. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol, 37: 3316–3322.
Buck C B, Pastrana D V, Lowy D R, et al. 2004. Efficient intracellular assembly of papillomaviral vectors. J Virol, 78: 751–757.
Calleja-Macias IE, Kalantari M, Allan B, et al. 2005. Papillomavirus subtypes are natural and old taxa: phylogeny of human papillomavirus types 44 and 55 and 68a and -b. J Virol, 78: 6565–6569.
Carter J J, Galloway D A. 1997. Humoral immune response to human papillomavirus infection. Clin Dermatol, 15: 249–259.
Carter JJ, Koutsky LA, Hughes JP, et al. 2000. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis, 181: 1911–1919.
Chan S Y, Bernard H U, Ong C K, et al. 1992. Phylogenetic analysis of 48 papillomavirus types and 28 subtypes and variants: a showcase for the molecular evolution of DNA viruses. J Virol, 66: 5714–5725.
Christensen N D, Kreider J W, Shah K V, et al. 1992. Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J Gen Virol, 73(5): 1261–1267.
Cui M H, Liu Y Q, Li H L, et al. 1994. Human papillomavirus in condyloma acuminata and other benign lesions of the female genital tract. Chin Med J (Engl), 107: 703–708.
de Villiers E M, Fauquet C, Broker T R, et al. 2004. Classification of papillomaviruses. Virology, 324:17–27.
Ferrera A, Velema J P, Figueroa M, et al. 1999. Human papillomavirus infection, cervical dysplasia and invasive cervical cancer in Honduras: a case-control study. Int J Cancer, 82: 799–803.
Gissmann L. 1996. Immunologic responses to human papillomavirus infection. Obstet Gynecol Clin North Am, 23: 625–639.
Huang S, Afonina I, Miller B A, et al. 1997. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Int J Cancer, 70: 408–411.
Leiserowitz GS, Hall KS, Foster CA, et al. 1997. Detection of serologic neutralizing antibodies against HPV-11 in patients with condyloma acuminata and cervical dysplasia using an in vitro assay. Gynecol Oncol, 66: 295–299.
Lo K W, Wong Y F, Chan M K, et al. 2002. Prevalence of human papillomavirus in cervical cancer: a multicenter study in China. Int J Cancer, 100: 327–331.
Pastrana D V, Buck C B, Pang Y Y, et al. 2004. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology, 321: 205–216.
Phelps W C, Alexander K A. 1995. Antiviral therapy for human papillomaviruses: rational and prospects. Ann Intern Med, 123: 368–382.
Schellekens M C, Dijkman A, Aziz M F, et al. 2004. Prevalence of single and multiple HPV types in cervical carcinomas in Jakarta, Indonesia. Gynecol Oncol, 93: 49–53.
Sigurdsson K, Taddeo F J, Benediktsdottir K R, et al. 2007. HPV genotypes in CIN 2–3 lesions and cervical cancer: a population-based study. Int J Cancer, 121: 2682–2687.
Stewart A C, Eriksson A M, Manos M M, et al. 1996. Intratype variation in 12 human papillomavirus types: a worldwide perspective. J Virol, 70: 3127–3136.
zur H H, de Villiers E M. 1994. Human papillomaviruses. Annu Rev Microbiol, 48: 427–447.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wu, Xl., Zhang, Ct., Zhu, Xk. et al. Detection of HPV types and neutralizing antibodies in women with genital warts in Tianjin City, China. Virol. Sin. 25, 8–17 (2010). https://doi.org/10.1007/s12250-010-3078-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12250-010-3078-4